3:44 PM
 | 
May 22, 2019
 |  BC Extra  |  Clinical News

May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s
Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week 12 vs. placebo in the Phase II SERENITY trial to treat moderately to severely active Crohn’s disease. The pharma plans to start this year a Phase III trial of the humanized IgG4 mAb that binds the IL-23...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >